Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eltoprazine SCHEMBL679616 | 0.98 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL9466563 | 0.98 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL29438749 | 0.98 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL31235563 | 0.98 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL1651102 | 0.97 | ADRB1 (0.94) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL4243350 | 0.94 | ADRB1 (0.88) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5253570 | 0.92 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5246531 | 0.92 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL27615104 | 0.90 | ADRB1 (0.81) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL6266386 | 0.87 | ADRB1 (0.77) | ADRB1DRD2DRD1HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 932 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2004082584-A2 | 5HT2C RECEPTOR ANTAGONISTS IN THE TREATMENT OF SCHIZOPHRENIA | CURIDIUM LIMITED (GB) | 2004-09-30 | — | — | WO | claimed |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | PHARMACIA CORPORATION (US) | 2004-07-29 | — | — | US | claimed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| CN-1131861-C | Piperazidine deriv. and preparing method thereof | AMERICAN HOME PROD (US) | 2003-12-24 | — | — | CN | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1309127-A | Piperazidine deriv. and preparing method thereof | AMERICAN HOME PROD (US) | 2001-08-22 | — | — | CN | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-0839146-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1A ANTAGONISTS | AMERICAN HOME PROD (US) | 2000-09-13 | — | — | EP | claimed |
| CN-1190968-A | Piperazine derivatives and their use as 5-HT 1A antagonists | AMERICAN HOME PROD (US) | 1998-08-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | HTR2A, HTR1A, TPH2 | ADRB1 182/4885DRD2 216/4885DRD1 477/4885 |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | ADRB1 41/4885DRD2 207/4885DRD1 415/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | ADRB1 41/4885DRD2 207/4885DRD1 415/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | ADRB1 127/4885DRD2 345/4885DRD1 1269/4885 |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | ADRB1 41/4885DRD2 207/4885DRD1 415/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | ADRB1 524/4885DRD2 38/4885DRD1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.